JaLCDOI 10.18926/AMO/56873
FullText URL 73_3_279.pdf
Author Makimoto, Go| Nishimori, Hisakazu| Kondo, Reiko| Yanai, Hiroyuki| Sugimoto, Morito| Oda, Naohiro| Kubo, Toshio| Hotta, Katsuyuki| Tabata, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu|
Abstract Urothelial carcinoma usually presents with hematuria, but cases of multiple lymphadenopathy with elevated S-pancreas-1 antigen (SPan-1) levels have not been reported. A 62-year-old Japanese man with lymphadenopathies was diagnosed with an adenocarcinoma of unknown origin and transferred to our hospital for further diagnosis. Serum carbohydrate antigen 19-9 and SPan-1 levels were extremely elevated. Uroplakin III immunostaining was positive in the inguinal lymph node, and cystoscopy revealed the presence of invasive urothelial carcinoma. Treatment with cisplatin and gemcitabine promoted a complete metabolic response for > 4 years. The detection of uroplakin III and serum SPan-1 might help diagnose urothelial carcinoma.
Keywords urothelial carcinoma uroplakin III s-pancreas-1 antigen carbohydrate antigen 19-9 chemotherapy
Amo Type Case Report
Published Date 2019-06
Publication Title Acta Medica Okayama
Volume volume73
Issue issue3
Publisher Okayama University Medical School
Start Page 279
End Page 284
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31235978
JaLCDOI 10.18926/AMO/56652
FullText URL 73_2_161.pdf
Author Okamoto, Sachiyo| Matsuoka, Ken-ichi| Sakamoto, Maiko| Usui, Yoshiaki| Fujiwara, Yuki| Kondo, Takumi| Tani, Katsuma| Saeki, Kyosuke| Meguri, Yusuke| Asada, Noboru| Ennishi, Daisuke| Nishimori, Hisakazu| Fujii, Keiko| Fujii, Nobuharu| Maeda, Yoshinobu|
Abstract Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.
Keywords allogeneic stem cell transplantation haploidentical stem cell transplantation relapse anti-T lymphocyte globulin
Amo Type Original Article
Published Date 2019-04
Publication Title Acta Medica Okayama
Volume volume73
Issue issue2
Publisher Okayama University Medical School
Start Page 161
End Page 171
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31015751
JaLCDOI 10.18926/AMO/56249
FullText URL 72_5_507.pdf
Author Ogata, Takeshi| Katsui, Kuniaki| Yoshio, Kotaro| Ihara, Hiroki| Katayama, Norihisa| Soh, Junichi| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
Abstract To clarify the relationship between dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) after surgery in cases of non-small cell lung cancer (NSCLC) treated with induction concurrent chemoradiotherapy (CCRT). Patients with NSCLC treated with induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 2.0 Gy fractions once daily for a total of 46 Gy) before surgery were reviewed. We calculated the percentage of lung volume receiving at least 20 Gy (V20) and the mean lung dose (MLD) for the total lung volume and the lung remaining after resection. Factors affecting the incidence of RP at grade 2 or higher (≥ G2 RP) were analyzed. Eighteen of 49 patients (37%) experienced ≥G2 RP. The V20 and MLD for the lung remaining after resection (V20r and MLDr) were significant predictors according to the multivariate analysis (p=0.007 and 0.041, respectively). The incidence of ≥G2 RP was 8% in patients with V20r<10%, and 13% in patients with MLDr<5.6 Gy, respectively. The optimal approach to reduce the rate of postoperative RP in patients with induction CCRT for NSCLC is to keep the V20r below 10% and/or the MLDr below 5.6 Gy in the radiotherapy planning.
Keywords radiation pneumonitis V20 mean lung dose induction chemoradiotherapy non-small cell lung cancer
Amo Type Original Article
Published Date 2018-10
Publication Title Acta Medica Okayama
Volume volume72
Issue issue5
Publisher Okayama University Medical School
Start Page 507
End Page 513
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30369608
JaLCDOI 10.18926/AMO/56080
FullText URL 72_3_319.pdf
Author Makimoto, Go| Ichihara, Eiki| Hotta, Katsuyuki| Ninomiya, Kiichiro| Oze, Isao| Minami, Daisuke| Ninomiya, Takashi| Kubo, Toshio| Ohashi, Kadoaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Abstract Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
Keywords cisplatin mannitol furosemide lung cancer hydration non-small cell lung cancer
Amo Type Clinical Study Protocol
Published Date 2018-06
Publication Title Acta Medica Okayama
Volume volume72
Issue issue3
Publisher Okayama University Medical School
Start Page 319
End Page 323
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29926012
FullText URL blood_119_1_285.pdf
Author Nishimori, Hisakazu| Maeda, Yoshinobu| Teshima, Takanori| Sugiyama, Haruko| Kobayashi, Koichiro| Yamasuji, Yoshiko| Kadohisa, Sachiyo| Uryu, Hidetaka| Takeuchi, Kengo| Tanaka, Takehiro| Yoshino, Tadashi| Iwakura, Yoichiro| Tanimoto, Mitsune|
Note This research was originally published in Blood. 2012. © the American Society of Hematology.
Published Date 2012-01-05
Publication Title Blood
Volume volume119
Issue issue1
Start Page 285
End Page 295
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version publisher
PubMed ID 22077062
DOI 10.1182/blood-2011-01-332478
Web of Sience KeyUT 000299012400035
Related Url https://doi.org/10.1182/blood-2011-01-332478
FullText URL K0005304 other1.pdf
Author Igawa, Takuro| Sato, Yasuharu| Takata, Katsuyoshi| Iwaki, Noriko| Tanaka, Takehiro| Asano, Naoko| Maeda, Yoshinobu| Orita, Yorihisa| Nakamura, Naoya| Nakamura, Shigeo| Yoshino, Tadashi|
Keywords Cyclin D2 CD5 Diffuse large B-cell lymphoma
Note 学位審査副論文
Published Date 2013-05-15
Publication Title Diagnostic Pathology
Volume volume8
Publisher BioMed Central
Start Page 81
ISSN 1746-1596
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
File Version publisher
PubMed ID 23675804
DOI 10.1186/1746-1596-8-81
Web of Sience KeyUT 000319266300002
Related Url https://doi.org/10.1186/1746-1596-8-81 http://ousar.lib.okayama-u.ac.jp/54287